Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for TNXP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 -33.27M
March 31, 2026 -20.20M
December 31, 2025 -59.50M
September 30, 2025 -100.28M
June 30, 2025 -13.99M
March 31, 2025 -59.18M
December 31, 2024 -85.42M
September 30, 2024 -44.65M
June 30, 2024 -10.55M
March 31, 2024 -0.023M
December 31, 2023 -41.29M
September 30, 2023 -6.324M
June 30, 2023 -0.8755M
March 31, 2023 11.50M
December 31, 2022 -7.910M
September 30, 2022 4.297M
June 30, 2022 -70.35M
March 31, 2022 -13.06M
December 31, 2021 -43.65M
September 30, 2021 -36.64M
June 30, 2021 -21.74M
March 31, 2021 -108.71M
December 31, 2020 -41.56M
September 30, 2020 -22.95M
June 30, 2020 -34.58M
Date Value
March 31, 2020 -28.76M
December 31, 2019 -7.951M
September 30, 2019 -4.530M
June 30, 2019 -0.4186M
March 31, 2019 -0.07M
December 31, 2018 -16.84M
September 30, 2018 -2.892M
June 30, 2018 -2.865M
March 31, 2018 -0.532M
December 31, 2017 -1.066M
September 30, 2017 0.1703M
June 30, 2017 -16.47M
March 31, 2017 -1.102M
December 31, 2016 -4.857M
September 30, 2016 -3.858M
June 30, 2016 -11.78M
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 -18.69M
June 30, 2015 0.054M
March 31, 2015 -29.05M
December 31, 2014 5.358M
September 30, 2014 -7.651M
June 30, 2014 -0.131M
March 31, 2014 -45.41M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Exelixis, Inc. 307.53M
Inovio Pharmaceuticals, Inc. -17.21M
Heron Therapeutics, Inc. -0.082M
ACADIA Pharmaceuticals, Inc. -10.49M
Alnylam Pharmaceuticals, Inc. -33.56M